What Researchers Did
Researchers reviewed 12 patients with bisphosphonate-associated osteonecrosis of the jaw to determine their bisphosphonate therapy details, presenting findings, comorbidities, and inciting events.
What They Found
They found that discontinuing bisphosphonate therapy did not reverse osteonecrosis, and surgical manipulation appeared to worsen the underlying bone pathology in these 12 patients. Hyperbaric oxygen offered no definitive benefit, and while antibiotic therapy controlled pain and swelling, it was ineffective in preventing the progression of the exposed bone.
What This Means for Canadian Patients
Canadian patients on bisphosphonate therapy should prioritize preventive strategies for osteonecrosis of the jaw, as current treatments like surgery or hyperbaric oxygen have shown limited effectiveness in reversing the condition. Managing symptoms with antibiotics may help, but preventing the initial development of osteonecrosis is crucial.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
A significant limitation is the small sample size of only 12 patients, which restricts the generalizability of the findings.